DBL Pharmaceuticals Inc., a concern of DBL Pharmaceuticals Ltd. is based in New York, USA. The company is currently holding ANDA of Methocarbamol 500 mg & 750 mg Tablet. It was a surprise debut of DBL Pharmaceuticals Inc. as the third Bangladeshi initiative in the US Generic Medicine market even before launching DBL Pharma in local territory.
In 2Q 2019, the company was named as the second largest seller of muscle relaxant “Methocarbamol” tablets, according to a report by IQVIA – an American health and clinical research company. The market report says, among the 13 generic (Methocarbamol) drug-selling companies, DBL Pharma holds 14.2% of the market share in US.
Methocarbamol is a widely used medicine to treat muscle pain in the US. After the expiration of the patent right of the innovator company, many Indian generic medicine companies started occupying the market share. Within only One and half year of launching DBL Pharmaceuticals Inc. grabbed this handsome market share. The company is working to extend the business in different portfolio.
DBL Pharmaceuticals Ltd. has built an advanced manufacturing facility in Bangladesh to comply all the regulatory guidelines of US FDA, UK MHRA and other regulatory standards of the world. In future, both the company (DBL Pharma, USA & DBL Pharma, BD) will jointly work to ensure the supply of quality medicine globally.